SPOTLIGHT -
Tony M. Keaveny, PhD, is the Founder and Chief Science Officer of O.N. Diagnostics.
Romosozumab outperforms teriparatide and denosumab in bone strength
A recent study found that romosozumab significantly outperformed teriparatide and denosumab in improving hip and spine bone strength.
Read More